Guo Guangchang: Fosun Firmly Advances Its Globalization Strategy
Guo Guangchang: Fosun Firmly Advances Its Globalization Strategy
HONG KONG, July 23, 2024 /PRNewswire/ -- "In the future, Fosun will continue to firmly advance its globalization strategy, transforming its globalization capability into sustained profit growth." Guo Guangchang, Chairman of Fosun International, said at the 2024 Fosun Semi-Annual Working Meeting on 20 July 2024. "Fosun's globalization is not a strategy which commences today, but has been going on for a very long period of time. We have become one of the few Chinese enterprises rooted in China with the capability to operate globally, that we are particularly proud of it."
"未來,復星將繼續堅定推進其全球化策略,將其全球化能力轉化爲持續的利潤增長。"復星國際主席郭廣昌在2024年7月20日的2024年復星半年度工作會議上說。"復星的全球化不是今天開始的策略,而是已經進行了很長一段時間。我們已成爲中國企業中少數在中國扎根並具備全球運營能力的企業之一,我們爲此感到特別自豪。"
Fosun has developed along the path of globalization for nearly 17 years. Fosun International started its globalization journey in 2007 when it was listed in Hong Kong. In the following decade, Fosun seized opportunities, continuously allocated global high-quality assets, expanded its diversified businesses, strengthened its industrial chain, and gradually built a global industrial ecosystem in line with its development logic. Today, Fosun has a profound business presence in more than 35 countries and regions around the world. In 2023, Fosun's overseas revenue reached RMB89.2 billion, accounting for 45% of its total revenue, with a 10-year compound annual growth rate of 55%.
復星已發展了近17年的全球化之路。復星國際在2007年在香港上市時開始了其全球化之旅。在接下來的十年,復星抓住機遇,不斷配置全球高質量資產,擴大其多元化業務,加強其產業鏈,並根據其發展邏輯逐步建立了全球產業生態系統。如今,復星在全球35多個國家和地區擁有深入的業務佈局。2023 年,復星海外收入達到892億元,佔總收入的45%, 10年複合年增長率達到55%。
With Fosun's businesses spread across the globe, how can it further integrate different industries and resources in various countries and regions, enhance the global operation capabilities of its member companies, and tap into potential values?
復星的業務遍佈全球,如何進一步整合各國和地區不同的行業和資源,增強其成員公司的全球運營能力,併發掘潛在價值?
Guo Guangchang believes that the most important thing is to transform globalization capabilities into dividends and profit growth. "The extent of global layout and globalization capability differ with our member companies and business units. We would like to see each business doing equally well. Besides the conventional overseas markets, it is hoped that competency would also be developed in the Middle East, Latin America, Southeast Asia and Africa."
郭廣昌認爲最重要的是將全球化能力轉化爲股息和利潤增長。"全球佈局和全球化能力在我們的成員公司和業務部門之間存在差異。我們希望看到每個業務都表現出色。除了傳統的海外市場,我們希望在中東、拉美、東南亞和非洲等地區發展能力建設。"
Club Med, the French-born global "premium all-inclusive" holiday resort brand officially joined Fosun in 2015. Guo Guangchang said Fosun's successful acquisition of Club Med is an important milestone to the Group's globalization. With nearly ten years of profound operation through continuous development of the global market, Club Med has now become one of the most important sources of revenue and profit for its parent company Fosun Tourism Group.
法國誕生的全球"高端全包"度假勝地品牌Club Med於2015年正式加入復星。郭廣昌說,復星成功收購Club Med 是集團全球化的一個重要里程碑。經過近十年的深入運作,通過不斷髮展全球市場,Club Med現已成爲其母公司復星旅遊文化的最重要的收入和利潤來源之一。
After years of development, the gene of globalization has been deeply rooted in all of Fosun's business segments. Fosun Pharma is one of the earliest representatives of Fosun's member companies to "go global". As early as 2007, Fosun Pharma entered the African market as a leading developer and manufacturer of antimalarial drugs. Today, its sales network covers more than 30 African countries and regions. Empowered by Fosun under the global ecosystem, Fosun Pharma's world-engaging integrated innovative model is maturing progressively.
經過多年的發展,全球化基因已經深入到了復星的所有業務領域。復星醫藥是復星成員公司中最早的"走出去"代表之一。早在2007年,復星醫藥就作爲一家領先的抗瘧藥物研發和生產商進入非洲市場。如今,它的銷售網絡覆蓋了30多個非洲國家和地區。在復星的全球生態系統下,復星醫藥的全球一體化創新模式正在逐步成熟。
In June this year, Fosun Pharma announced its plan to privatise its subsidiary Shanghai Henlius. As an outstanding representative of domestically developed innovative drugs, Shanghai Henlius has developed a number of innovative drugs such as HANQUYOU and HANSIZHUANG, and its capabilities of manufacturing and commercializing self-developed innovative drugs to meet the needs of patients in different regions have gained high market recognition. For instance, HLX02 (trastuzumab, trade name: HANQUYOU in China, HERCESSI in the U.S. and Zercepac in Europe) is the first "China-made" monoclonal biosimilar approved in China, European Union, and U.S. and was approved to be marketed in more than 40 countries and regions around the world. In 2023, Shanghai Henlius became the first profit-making Hong Kong-listed "18A" biopharmaceutical company, achieving annual net profit of RMB546 million.
今年6月,復星醫藥宣佈計劃私有化其子公司復宏漢霖。作爲國內自主開發創新藥物的傑出代表,復宏漢霖研製了一批創新性藥物,如HANQUYOU和HANSIZHUANG,並具備生產和商業化自行研發的創新藥物以滿足不同地區患者需求的能力,在市場上得到了很高的認可。例如,HLX02(曲妥珠單抗,商品名:中國的HANQUYOU,在美國的HERCESSI和歐洲的Zercepac)是首個獲批在中國、歐洲和美國銷售的"中國製造"單克隆生物類似物。在2023年,復宏漢霖成爲首家實現港股18A生物醫藥公司的淨利潤達到5,4600萬元的公司。
"Globalization must also be pursued by our overseas companies, Fidelidade is doing very good in this aspect." At the meeting on 20 July, Guo Guangchang included Fidelidade as one of the "honor companies" and encouraged more Fosun overseas member companies to expand their global businesses. Data shows that the global operation capability of Fidelidade remarkably enhanced after it has joined Fosun. Besides maintaining its leadership in Portugal, Fidelidade's premium percentage in overseas markets also increased from 6% in 2017 to 33% in 2023. With the steady expansion of its business scale, Fidelidade has continuously improved its profitability, achieving a net profit of EUR180 million in 2023.
"全球化也必須由我們的海外公司追求,保險業務Fidelidade在這方面做得很好。"在7月20日的會議上,郭廣昌將Fidelidade作爲"榮譽公司"之一,並鼓勵更多復星海外成員公司擴展其全球業務。數據顯示,Fidelidade加入復星後其全球運營能力顯著提升。除了在葡萄牙保持領先地位外,Fidelidade在海外市場的保費比例也從2017年的6%增加到2023年的33%。隨着業務規模的穩步擴大,Fidelidade的盈利能力不斷提高,2023年實現了1.8億歐元的淨利潤。
In response to repeated appeals for deglobalization recent years, Guo Guangchang said: "The main trend of opening up integration of globalization will remain unchanged in the long term, we believe Fosun has been persistently in doing the right thing and will continue to do so."
針對近年來反全球化的反覆呼聲,郭廣昌表示: "長期來看,全球化的開放一體化主要趨勢將不會改變,我們相信復興集團一直在做正確的事情,並將繼續這樣做。"
SOURCE Fosun
資料來源:中國平安
譯文內容由第三人軟體翻譯。